Delcath Systems (DCTH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
The annual meeting will be held virtually on May 13, 2026, with voting on four key proposals and no physical attendance option.
Proposals include electing two directors, amending the equity incentive plan, ratifying the external auditor, and a say-on-pay advisory vote.
Only stockholders of record as of March 16, 2026, are entitled to vote, with detailed instructions for proxy and virtual voting.
The Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1: Elect Elizabeth Czerepak and John R. Sylvester as Class II directors for terms expiring in 2029.
Proposal 2: Approve an amendment to the 2020 Omnibus Equity Incentive Plan to add 1,800,000 shares.
Proposal 3: Ratify CBIZ CPAs P.C. as the independent auditor for fiscal year 2026.
Proposal 4: Approve, on a non-binding basis, executive compensation as disclosed.
Shareholder proposals for the 2027 meeting must be submitted at least 120 days before the anniversary of the 2026 proxy statement release.
Board of directors and corporate governance
The Board consists of six members, with a majority classified as independent under Nasdaq rules.
Board leadership is separated between the CEO and Non-Executive Chairman.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent chairs.
Board and committee attendance exceeded 75% for all directors in 2025.
The Board seeks diverse skills and backgrounds and considers shareholder recommendations for director nominees.
Latest events from Delcath Systems
- Virtual annual meeting to vote on directors, equity plan, auditor, and executive pay.DCTH
Proxy filing2 Apr 2026 - Record $85.2M revenue, positive net income, and strong 2026 growth outlook.DCTH
Q4 202526 Feb 2026 - Q2 revenue hit $7.8M with 80% margin; net loss widened, but U.S. growth and NTAP boost outlook.DCTH
Q2 20242 Feb 2026 - Q3 revenue hit $11.2M, net income $1.9M, and $25M raised from warrants; all debt eliminated.DCTH
Q3 202415 Jan 2026 - Registration allows up to $150M in securities to fund oncology growth and operations.DCTH
Registration Filing16 Dec 2025 - Board recommends approval of all proposals, including director elections and plan amendments.DCTH
Proxy Filing2 Dec 2025 - Virtual Annual Meeting to vote on directors, equity plans, auditor, and executive pay.DCTH
Proxy Filing2 Dec 2025 - FY2024 revenue hit $37.2M, driven by HEPZATO KIT and positive Q4 adjusted EBITDA.DCTH
Q4 20241 Dec 2025 - Q1 2025 saw $19.8M revenue, $1.1M net income, and strong U.S. expansion.DCTH
Q1 202526 Nov 2025